Tag Archives: AMP v. Myriad

BIO and University Organizations offer Support of STRONG Patents Act

shutterstock_26191726

On March 4, 2015, Senator Chris Coons (D-DE) introduced a new bill, The STRONG Patents Act of 2015. Sponsored alongside Sen. Richard Durbin (D-IL) and Sen. Mazie Hirono (D-HI), the bill is offered as a complement to House Judiciary Committee Chairman Goodlatte’s (R-VA) Innovation Act, which many in the biotech sector see as an imbalanced bill. The STRONG Patents Act of 2015 would target the abusive practices of patent trolls in a narrowly tailored setting, Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

BIO IPCC Spring Conference Program Announced

IPCC Logo

BIO’s 2015 IP Counsels Committee Spring Conference & Meeting will be held April 15-17 in St. Louis, Missouri, at the Four Seasons St. Louis Hotel. The biannual conference offers timely, relevant educational sessions on the latest issues in the biotech IP sector, informal networking events designed to promote discussion and foster relationships among industry colleagues, and practical tips for attendees to use the next day. Attendees will hear from the foremost experts in biotech IP Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , , , , , ,

Detailed Report Examines the Crucial Role of Patents in Genetic Testing

shutterstock_27291016

In The Critical Role of Patents in the Development, Commercialization, and Utilization of Innovative Genetic Diagnostic Tests, Professor Holman argues that advocates for weakening patent protection have fundamental misconceptions on the role of patents in genetic testing. Opponents assume that patents negatively impact patient access to genetic diagnostic testing. They believe that patents inhibit research that could lead to new or improved versions of genetic tests, and that patent holders charge higher prices as exclusive Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , ,

Whole Genome Sequencing and Myriad Supreme Court Case: Nothing to See Here

Supreme Court - Phil Roeder

Bio IT World just published an article stating that the Myriad Supreme Court case will have little to no effect on whole genome sequencing. “As WGS involves determining the sequence of an individual’s entire genome, there is concern in many quarters that WGS could violate essentially every patent covering an isolated human DNA sequence—of which there are thousands. Indeed, this concern has been raised by scholars, policy analysts and lawyers, including before the Federal Circuit Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , , , , ,

AMP v. Myriad: BIO Statement on Federal Circuit (Re)Decision

courtroom

BIO released the following statement on the Federal Circuit’s decision in the AMP v. Myriad case on remand from the Supreme Court to reconsider in light of Mayo v. Prometheus. “Today’s decision by the U.S. Court of Appeals for the Federal Circuit confirms long-standing law under which valuable DNA preparations, bacterial enzymes, plant-derived antibiotics and other industrially and medically useful substances can be considered for patenting. Such patents have long provided critical incentives for expensive Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,